Ad
related to: why is bluebird stock downlp.stockstotrade.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Bluebird Bio (NASDAQ: BLUE) shares are trading lower on Thursday after the company reported third-quarter earnings results. BMO also downgraded the stock from Outperform to Market Perform with a ...
bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.
For premium support please call: 800-290-4726 more ways to reach us
With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.
Yahoo Finance's Julie Hyman discusses the reversal in Bluebird Bio shares after the FDA approved its second gene therapy.
Here is why now is as good a time as any to "buy low" when it comes to this stock. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy ...
Shares in Bluebird were down 0.2% at $57 in Tuesday’s pre-market trading in the U.S. after plunging 34% year-to-date.Bluebird is also giving the underwriters a 30-day option to buy up to an ...
It won't be easy for the company to bounce back. For premium support please call: 800-290-4726 more ways to reach us